Denali therapeutics to present interim data from phase 1/2 study of etv:ids (dnl310) for the potential treatment of hunter syndrome at mps 2021

Management to host webinar for analysts and investors on july 25th management to host webinar for analysts and investors on july 25th

DNLI Ratings Summary

DNLI Quant Ranking